Neuroone Medical Technologies CORP 8-K Filing

Ticker: NMTC · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1500198

Neuroone Medical Technologies CORP 8-K Filing Summary
FieldDetail
CompanyNeuroone Medical Technologies CORP (NMTC)
Form Type8-K
Filed DateDec 22, 2025
Pages3
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Neuroone Medical Technologies CORP (ticker: NMTC) to the SEC on Dec 22, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar).

How long is this filing?

Neuroone Medical Technologies CORP's 8-K filing is 3 pages with approximately 988 words. Estimated reading time is 4 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 988 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2025-12-22 08:13:50

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On December 22, 2025 the Company posted an updated corporate presentation to its website at https://nmtc1.com/investors, which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.2 to this Current Report. Exhibit 99.2 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.2 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. In accordance with General Instruction B.2. of Form 8-K, the information contained in this Item 7.01 of this Current Report, including Exhibit 99.2 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. The Company's submission of this Current Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 22, 2025 99.2 Corporate Deck, dated December 2025 104 Cover Page Interactive Data File (embedded with Inline XBRL docum

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: December 22, 2025 By: /s/ David Rosa David Rosa Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing